Medeon Biodesign (6499) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medeon Biodesign (6499) has a cash flow conversion efficiency ratio of -0.074x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-93.35 Million ≈ $-2.94 Million USD) by net assets (NT$1.27 Billion ≈ $39.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Medeon Biodesign for the company's overall valuation and market capitalisation.
Medeon Biodesign - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Medeon Biodesign's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medeon Biodesign Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medeon Biodesign ranked by their cash flow conversion efficiency. Explore Medeon Biodesign (6499) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taaleri Oyj
HE:TAALA
|
0.010x |
|
Signature International Bhd
KLSE:7246
|
0.018x |
|
Exco Technologies Limited
TO:XTC
|
0.053x |
|
Grupo Gicsa S.A. de C.V
MX:GICSAB
|
0.019x |
|
PT Multikarya Asia Pacific Ray
JK:MKAP
|
0.080x |
|
BF Utilities Limited
NSE:BFUTILITIE
|
0.229x |
|
Kaltura Inc
NASDAQ:KLTR
|
-1.154x |
|
Nanhua Instruments Co Ltd
SHE:300417
|
0.011x |
Annual Cash Flow Conversion Efficiency for Medeon Biodesign (2017–2025)
The table below shows the annual cash flow conversion efficiency of Medeon Biodesign from 2017 to 2025. View 6499 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.54 Billion ≈ $48.42 Million |
NT$-629.14 Million ≈ $-19.82 Million |
-0.409x | +24.49% |
| 2024-12-31 | NT$1.54 Billion ≈ $48.39 Million |
NT$-832.66 Million ≈ $-26.23 Million |
-0.542x | -70.27% |
| 2023-12-31 | NT$2.37 Billion ≈ $74.72 Million |
NT$-755.08 Million ≈ $-23.79 Million |
-0.318x | -152.84% |
| 2022-12-31 | NT$3.66 Billion ≈ $115.42 Million |
NT$-461.34 Million ≈ $-14.53 Million |
-0.126x | -79.78% |
| 2021-12-31 | NT$4.19 Billion ≈ $131.96 Million |
NT$-293.38 Million ≈ $-9.24 Million |
-0.070x | -22.59% |
| 2020-12-31 | NT$2.65 Billion ≈ $83.41 Million |
NT$-151.27 Million ≈ $-4.77 Million |
-0.057x | +46.90% |
| 2019-12-31 | NT$2.25 Billion ≈ $70.85 Million |
NT$-241.99 Million ≈ $-7.62 Million |
-0.108x | -160.10% |
| 2018-12-31 | NT$1.80 Billion ≈ $56.66 Million |
NT$322.05 Million ≈ $10.15 Million |
0.179x | +188.32% |
| 2017-12-31 | NT$1.53 Billion ≈ $48.29 Million |
NT$-310.76 Million ≈ $-9.79 Million |
-0.203x | -- |
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more